North America Glp-1 Agonists Weight Loss Drugs Market Size & Outlook
Global Market
Related Markets
North America glp-1 agonists weight loss drugs market highlights
- The North America glp-1 agonists weight loss drugs market generated a revenue of USD 16,105.4 million in 2025.
- The market is expected to grow at a CAGR of 13.83% from 2026 to 2033.
- In terms of segment, semaglutide (wegovy) was the largest revenue generating drug in 2025.
- Tirzepatide (Zepbound) is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 16,105.4 million |
| Market revenue in 2033 | USD 52,827.5 million |
| Growth rate | 13.83% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (wegovy) |
| Fastest growing segment | Tirzepatide (Zepbound) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Wegovy), Tirzepatide (Zepbound), Liraglutide (Saxenda), Other Drugs |
| Key market players worldwide | Eli Lilly and Company, Pfizer Inc, Novo Nordisk A/S ADR, Viking Therapeutics Inc, Structure Therapeutics |
Other key industry trends
- In terms of revenue, North America region accounted for 77.2% of the global glp-1 agonists weight loss drugs market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- North America is the fastest growing regional market and is projected to reach USD 52,827.5 million by 2033.
North America dominated the GLP-1 agonists weight loss drugs market with the largest revenue share of 75.50% in 2024.
Driven by the increasing prevalence of obesity and related conditions, the demand for GLP-1 agonists, such as Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is rising.
The market is also benefiting from a shift toward more accessible treatment options, with both parenteral and oral formulations available in retail and hospital pharmacies.
No credit card required*
Publish Date: Feb 03, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Agonists Weight Loss Drugs Market Scope
GLP-1 Agonists Weight Loss Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | www.vikingtherapeutics.com |
| Structure Therapeutics | View profile | 101-250 | South San Francisco, California, United States, North America | structuretx.com/ |
| Eli Lilly and Company | View profile | - | - | - |
North America GLP-1 Agonists Weight Loss Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Agonists Weight Loss Drugs Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Wegovy) was the largest segment with a revenue share of 79.75% in 2025.
Horizon Databook has segmented the North America glp-1 agonists weight loss drugs market based on semaglutide (wegovy), tirzepatide (zepbound), liraglutide (saxenda), other drugs covering the revenue growth of each sub-segment from 2021 to 2033.
North America dominated the GLP-1 agonists weight loss drugs market with the largest revenue share of 75.50% in 2024.
Driven by the increasing prevalence of obesity and related conditions, the demand for GLP-1 agonists, such as Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is rising.
The market is also benefiting from a shift toward more accessible treatment options, with both parenteral and oral formulations available in retail and hospital pharmacies.
- North America Glp-1 Agonists Weight Loss Drugs Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Wegovy)
- Liraglutide (Saxenda)
- Tirzepatide (Zepbound)
- Other Drugs
- North America Glp-1 Agonists Weight Loss Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Parenteral
- Oral
- North America Glp-1 Agonists Weight Loss Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Retail Pharmacies
- Hospital Pharmacies
- Other Pharmacies
Reasons to subscribe to GLP-1 Agonists Weight Loss Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Agonists Weight Loss Drugs Market Outlook databook
- Our clientele includes a mix of GLP-1 Agonists Weight Loss Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America GLP-1 Agonists Weight Loss Drugs Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America GLP-1 Agonists Weight Loss Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Glp-1 Agonists Weight Loss Drugs Market, 2021-2033 (US$M)
North America glp-1 agonists weight loss drugs market statistics, by drug, 2021-2033 (US$M)
